Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

22nd Century Group Inc XXII

22nd Century Group, Inc. is an agricultural biotechnology company. The Company is focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. Additionally, the Company provide contract manufacturing services for conventional combustible tobacco products for third-party brands. The Company operates through a single segment named Tobacco. Its tobacco segment is engaged in contract manufacturing organization (CMO) customer contracts that consist of obligations to manufacture the customers' branded filtered cigars and cigarettes. The tobacco segment is engaged in the sale of its reduced nicotine content (RNC) cigarettes, sold under the brand name VLN, or research cigarettes sold under the brand name SPECTRUM. It uses plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products.


NDAQ:XXII - Post by User

Post by lelianicruzon Sep 27, 2024 7:30am
35 Views
Post# 36243632

$XXII:Pioneering Reduced-Risk Smoking with VLN® Cigarettes

$XXII:Pioneering Reduced-Risk Smoking with VLN® Cigarettes

In the rapidly evolving tobacco industry, 22nd Century Group, Inc. ($XXII) is emerging as a pioneer with its innovative smoking alternatives. The company's flagship product, VLN® cigarettes, has gained widespread attention as the world’s first and only combustible cigarette to earn the Modified Risk Tobacco Product (MRTP) designation from the U.S. Food and Drug Administration (FDA). This recognition positions 22nd Century at the forefront of the market focused on reduced harm and safer smoking options.

VLN® Cigarettes represent a game changer in the industry, containing up to 95% less nicotine than traditional cigarettes. They are designed for adult smokers seeking to reduce nicotine intake or quit smoking altogether. The MRTP designation signifies the FDA’s acknowledgment of VLN® as a product that could benefit public health by reducing addiction risk and offering a safer smoking experience.

The company’s bold mission, "The mission is to sell the last cigarette before the 22nd Century," reflects its commitment to harm reduction and responsible tobacco use. As global trends shift towards sustainable and reduced-risk products, 22nd Century Group’s innovative approach makes it a promising contender in this market.

<< Previous
Bullboard Posts
Next >>